ImmunityBio (IBRX) said Wednesday it has received the US Food and Drug Administration's authorization for an expanded access program to provide recombinant Bacillus Calmette-Guerin, addressing the nationwide shortage of TICE BCG for bladder cancer treatment.
The alternative BCG, developed by the Serum Institute of India, has performed well in European trials for non-muscle invasive bladder cancer, exhibiting strong immunogenicity and enhanced safety over previous strains.
ImmunityBio said that rBCG supplies are now available, with shipments starting immediately through an FDA Expanded Access Program.
Shares of ImmunityBio were up more than 8% in recent Wednesday trading.
Price: 3.62, Change: +0.27, Percent Change: +8.06
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。